Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Diseases
  Free Subscription

Articles published in
J Gastroenterol
    October 2026
  1. KUO CC, Chen CH, Kuo HT, Lai CC, et al
    Clinical outcomes of lean metabolic dysfunction-associated steatotic liver disease by phenotypic subtypes.
    J Gastroenterol. 2026;61:1471-1482.
    >> Share

    September 2026
  2. SUZUKI T, Matsuura K, Hashimoto Y, Okina M, et al
    B cell receptor-associated protein 31 levels in serum-derived extracellular vesicles are associated with therapeutic response and prognosis in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab: a multicenter study
    J Gastroenterol. 2026 Sep 4. doi: 10.1007/s00535-026-02515.
    >> Share

    August 2026
  3. NAKAJIMA A, Okanoue T, Hiasa Y, Takahashi H, et al
    Semaglutide in Japanese participants with metabolic dysfunction-associated steatohepatitis: a subgroup analysis of the ESSENCE trial.
    J Gastroenterol. 2026 Aug 28. doi: 10.1007/s00535-026-02507.
    >> Share

  4. ZHOU LX, Wan BY, Dong H, Shi AL, et al
    Reply to: comment on "Validation of Baveno VII criteria for recompensation in patients with decompensated cirrhosis treated by laparoscopic splenectomy and azygoportal disconnection".
    J Gastroenterol. 2026 Aug 10. doi: 10.1007/s00535-026-02497.
    >> Share

    July 2026
  5. YASUDA K, Iida N, Takeshita Y, Masuo Y, et al
    Tofogliflozin alters amino acid metabolism in gut microbiota linked to hepatic transcriptomic signatures in MASLD.
    J Gastroenterol. 2026 Jul 30. doi: 10.1007/s00535-026-02488.
    >> Share

  6. FAN Z, Li L
    Comment on "Intestinal obstruction impairs the antitumor function of hepatic natural killer cells against colorectal cancer".
    J Gastroenterol. 2026 Jul 28. doi: 10.1007/s00535-026-02490.
    >> Share

  7. SEKO Y, Yamaguchi K
    Management of MASLD/MASH: challenges, innovations, and the future of patient-centered care in Japan.
    J Gastroenterol. 2026;61:880-908.
    >> Share

    June 2026
  8. YASUURA N, Suda G, Ohara M, Yokoyama D, et al
    Alcohol involvement may modify the association between previous hepatitis B virus infection and hepatocellular carcinoma risk in steatotic liver disease.
    J Gastroenterol. 2026 Jun 26. doi: 10.1007/s00535-026-02473.
    >> Share

  9. SOUSA JM, Rodriguez-Tajes S, Hernandez-Guerra M, Casado M, et al
    Prevalence and incidence of chronic kidney disease in patients with primary biliary cholangitis.
    J Gastroenterol. 2026 Jun 22. doi: 10.1007/s00535-026-02442.
    >> Share

  10. AKUTA N, Kogiso T, Ikejima K, Otsuka M, et al
    Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026.
    J Gastroenterol. 2026;61:693-710.
    >> Share

  11. KAWATA K, Takahashi H, Arai T, Seko Y, et al
    Impact of cardiometabolic criteria on the pathogenesis of MASLD and diagnostic performance of non-invasive tests.
    J Gastroenterol. 2026;61:783-795.
    >> Share

    May 2026
  12. SONG C, Zhou Z, Li X
    Comment on "Validation of Baveno VII criteria for recompensation in patients with decompensated cirrhosis treated by laparoscopic splenectomy and azygoportal disconnection".
    J Gastroenterol. 2026 May 18. doi: 10.1007/s00535-026-02444.
    >> Share

  13. MIWA T, Hsu CL, Shimizu M, Bloom PP, et al
    Covert hepatic encephalopathy as a multi-organ syndrome: the gut-liver-muscle-brain axis, diagnosis, treatment, and multidisciplinary care.
    J Gastroenterol. 2026 May 8. doi: 10.1007/s00535-026-02425.
    >> Share

  14. HASHIMOTO D, Ikeura T, Maekawa A, Nakajima T, et al
    Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study.
    J Gastroenterol. 2026 May 4. doi: 10.1007/s00535-026-02432.
    >> Share

  15. OBA A, Taguchi T, Fujikawa N, Okami S, et al
    Clinical significance of gadoxetate sodium-enhanced MRI for detecting liver metastasis in patients with pancreatic cancer: decadal real-world data analysis in Japan.
    J Gastroenterol. 2026 May 4. doi: 10.1007/s00535-026-02431.
    >> Share

  16. YOSHIDA Y, Kumada T, Hirooka M, Ogawa S, et al
    Steatosis index: a novel multiparametric ultrasound approach for accurate liver steatosis quantification and grading.
    J Gastroenterol. 2026;61:592-602.
    >> Share

  17. WU J, Miao H, Yuan W, Yao Y, et al
    Single-cell transcriptomics unveils the immunologic landscape of anti-PD-1-associated indirect drug-induced liver injury.
    J Gastroenterol. 2026;61:603-624.
    >> Share

    April 2026
  18. KANAI M, Sakai A, Date T, Aoki Y, et al
    HBV-induced miR-4461 downregulation correlates with elevated fibrinogen alpha chain expression in hepatocellular carcinoma.
    J Gastroenterol. 2026 Apr 30. doi: 10.1007/s00535-026-02433.
    >> Share

  19. LIN C, Kang S, Zhang J, Yu W, et al
    The vessels encapsulating tumor clusters (VETC) pattern is a negative predictor for first-line immune checkpoint inhibitors alone in unresectable hepatocellular carcinoma.
    J Gastroenterol. 2026 Apr 24. doi: 10.1007/s00535-026-02421.
    >> Share

  20. IKEHARA T, Otsu H, Tobo T, Hosoda K, et al
    Novel driver gene FIRRM regulates the cell cycle for promoting tumor growth in hepatocellular carcinoma.
    J Gastroenterol. 2026 Apr 20. doi: 10.1007/s00535-026-02380.
    >> Share

  21. CHI CT, Huang YH
    Optimal treatment selection for hepatocellular carcinoma in the era of immunotherapy.
    J Gastroenterol. 2026 Apr 20. doi: 10.1007/s00535-026-02411.
    >> Share

  22. SHI F, Peng Z, Lian S, Mai Q, et al
    Lenvatinib plus hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and leucovorin versus lenvatinib alone for advanced hepatocellular carcinoma: a multicenter retrospective cohort study.
    J Gastroenterol. 2026 Apr 10. doi: 10.1007/s00535-026-02406.
    >> Share

  23. KUMADA T, Toyoda H, Ogawa S, Gotoh T, et al
    Comparative diagnostic performance of ultrasound-guided attenuation parameter versus B-mode scoring for hepatic steatosis assessment: an ordinal-scale statistical approach.
    J Gastroenterol. 2026 Apr 2. doi: 10.1007/s00535-026-02403.
    >> Share

  24. REN X, Yan C, Liu X, Jia X, et al
    Bifidobacterium bifidum CIP-01 attenuates metabolic dysfunction-associated steatotic liver disease induced by high-alcohol-producing Klebsiella pneumoniae.
    J Gastroenterol. 2026;61:462-476.
    >> Share

    March 2026
  25. ONO A, Miura R, Hayes CN, Kawaoka T, et al
    Reply to "IL-6 as a biomarker in atezolizumab plus bevacizumab in patients with hepatocellular carcinoma".
    J Gastroenterol. 2026 Mar 25. doi: 10.1007/s00535-026-02390.
    >> Share

  26. ZHANG F, Wang YS, Liu LX, Wang JZ, et al
    Reply to "Checking the shape of hepatocellular carcinoma: How irregular is irregular?".
    J Gastroenterol. 2026 Mar 21. doi: 10.1007/s00535-026-02394.
    >> Share

    February 2026
  27. SUN X, Zhang Y, Zhang X, Qin Q, et al
    Hepatocyte-specific yes-associated protein knockout exacerbates non-alcoholic steatohepatitis by upregulating PCSK9.
    J Gastroenterol. 2026 Feb 27. doi: 10.1007/s00535-026-02372.
    >> Share

  28. LIU J, Jia T
    Letter to the editor to ''Serum zinc levels as predictors of covert hepatic encephalopathy in patients with liver cirrhosis''.
    J Gastroenterol. 2026 Feb 24. doi: 10.1007/s00535-026-02375.
    >> Share

  29. ADNAN M, Khan S, Thasleem H, Imran J, et al
    IL-6 as a biomarker in atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    J Gastroenterol. 2026 Feb 21. doi: 10.1007/s00535-026-02360.
    >> Share

  30. HUO TI, Ho SY
    Checking the shape of hepatocellular carcinoma: how irregular is irregular?
    J Gastroenterol. 2026 Feb 8. doi: 10.1007/s00535-026-02359.
    >> Share

  31. IMAOKA K, Ohira M, Yano T, Bekki T, et al
    Intestinal obstruction impairs the antitumor function of hepatic natural killer cells against colorectal cancer.
    J Gastroenterol. 2026 Feb 6. doi: 10.1007/s00535-026-02349.
    >> Share

  32. MYOJIN Y, Hikita H
    Growth differentiation factor 15: from stress response to clinical utility in chronic liver diseases.
    J Gastroenterol. 2026;61:117-130.
    >> Share

    January 2026
  33. SHEN L, Lv T, Li S, Chen S, et al
    Factors associated with recompensation and criteria for etiological suppression in patients with primary biliary cholangitis.
    J Gastroenterol. 2026 Jan 13. doi: 10.1007/s00535-025-02342.
    >> Share

    December 2025
  34. REN B, Li H, Liu S, Huang Z, et al
    Hic-5 deficiency attenuates MAFLD by inhibiting neutrophils migration via the CXCL1-CXCR2 axis.
    J Gastroenterol. 2025;60:1535-1553.
    >> Share

  35. TSURUSAKI M, Sofue K, Murakami T, Tanigawa N, et al
    Evidence for imaging-based diagnosis of liver metastases from colorectal cancer.
    J Gastroenterol. 2025;60:1471-1480.
    >> Share

    November 2025
  36. INADA H, Kurano S, Miyamoto H, Onishi M, et al
    TP53 mutation predicts resistance to immune checkpoint inhibitor-based therapy in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2025 Nov 17. doi: 10.1007/s00535-025-02320.
    >> Share

  37. ZHOU LX, He CH, Dong H, Gao TM, et al
    Validation of Baveno VII criteria for recompensation in patients with decompensated cirrhosis treated by laparoscopic splenectomy and azygoportal disconnection.
    J Gastroenterol. 2025 Nov 8. doi: 10.1007/s00535-025-02317.
    >> Share

  38. HINO K, Nishina S, Yanatori I
    Ferroptosis: biology and role in liver disease.
    J Gastroenterol. 2025;60:1339-1361.
    >> Share

  39. TAKEMURA Y, Ueda Y, Takemura R, Mita J, et al
    Current status of waitlist mortality and transplant probability for adult candidates with chronic end-stage liver disease for deceased donor liver transplantation under the Model for End-Stage Liver Disease score-based allocation policy in Japan.
    J Gastroenterol. 2025;60:1414-1426.
    >> Share

    October 2025
  40. TAHATA Y, Hikita H, Takaki A, Kurosaki M, et al
    Long-term changes in hepatic reserve and prognosis after direct-acting antiviral treatment in patients with hepatitis C virus-related decompensated cirrhosis: a five-year follow-up study of a Japanese phase 3 trial.
    J Gastroenterol. 2025 Oct 30. doi: 10.1007/s00535-025-02312.
    >> Share

  41. MAESAKA K, Hikita H, Tahata Y, Nishioka C, et al
    Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma.
    J Gastroenterol. 2025 Oct 25. doi: 10.1007/s00535-025-02308.
    >> Share

  42. IWASA T, Miwa T, Utakata Y, Oi M, et al
    Development of overt hepatic encephalopathy increases mortality in patients with cirrhosis: a multicenter retrospective cohort study.
    J Gastroenterol. 2025 Oct 17. doi: 10.1007/s00535-025-02309.
    >> Share

  43. NAKADAI Y, Ojiro K, Kasuga R, Chu PS, et al
    Validation of novel scoring systems for acute decompensated cirrhosis identifies PBC as an independent poor prognostic factor: a single-center Japanese cohort study.
    J Gastroenterol. 2025 Oct 12. doi: 10.1007/s00535-025-02310.
    >> Share

  44. MIYAKE T, Yoshida O, Furukawa S, Sato Y, et al
    GPAM upregulation enhances hepatic fat deposition and reduces visceral adipose tissue in response to trans-fatty acids.
    J Gastroenterol. 2025 Oct 4. doi: 10.1007/s00535-025-02297.
    >> Share

  45. FUJII H, Uchida-Kobayashi S, Kanamori A, Nadatani Y, et al
    Defining optimal fatty liver index thresholds for MASLD and MetALD using controlled attenuation parameter as reference.
    J Gastroenterol. 2025;60:1296-1309.
    >> Share

  46. LEE J, Cha JH, Cho HS, Yang K, et al
    The PNPLA3 I148M variant is associated with immune cell infiltration and advanced fibrosis in MASLD: a prospective genotype-phenotype study.
    J Gastroenterol. 2025;60:1284-1295.
    >> Share

    August 2025
  47. OHAMA H, Hiraoka A, Tada T, Hirooka M, et al
    Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma.
    J Gastroenterol. 2025 Aug 20. doi: 10.1007/s00535-025-02290.
    >> Share

  48. KIDO H, Mizukoshi E, Yanagi M, Shihui L, et al
    Abnormalities of intracellular organelles in metabolic dysfunction-associated steatotic disease.
    J Gastroenterol. 2025;60:990-999.
    >> Share

    July 2025
  49. YAMASAKI S, Nakahara T, Tsuge M, Yamaoka K, et al
    Metabolic dysfunction-associated steatotic liver disease affects the development of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients.
    J Gastroenterol. 2025 Jul 7. doi: 10.1007/s00535-025-02270.
    >> Share

  50. TSUTSUMI T, Kawaguchi T, Fujii H, Kamada Y, et al
    Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis.
    J Gastroenterol. 2025;60:891-904.
    >> Share

  51. SUZUKI T, Matsuura K, Tahata Y, Hikita H, et al
    Posttreatment serum CXCL10 level stratifies survival in compensated and decompensated cirrhotic patients due to chronic hepatitis C virus infection after direct-acting antiviral therapy.
    J Gastroenterol. 2025 Jul 1. doi: 10.1007/s00535-025-02282.
    >> Share

    June 2025
  52. OFUCHI T, Otsu H, Hosoda K, Ikehara T, et al
    VPS45 promotes the progression of hepatocellular carcinoma by recycling beta1 integrin to the cell membrane via the endocytic pathway.
    J Gastroenterol. 2025 Jun 20. doi: 10.1007/s00535-025-02278.
    >> Share

  53. KAWAGISHI N, Suda G, Tahata Y, Hikita H, et al
    Pretreatment serum angiopoietin-2 predicts prognosis and liver functional reserve after successful HCV eradication with sofosbuvir and velpatasvir in patients with HCV-related decompensated cirrhosis.
    J Gastroenterol. 2025 Jun 20. doi: 10.1007/s00535-025-02275.
    >> Share

  54. LIU WM, Chen CY, Ma HQ, Zhang QQ, et al
    Inhibition of liver cancer cell growth by metabolites S-adenosylmethionine and nicotinic acid originating from liver progenitor cells.
    J Gastroenterol. 2025;60:754-769.
    >> Share

    May 2025
  55. ONO A, Hayes CN, Miura R, Kawaoka T, et al
    Noninvasive prediction of the clinical benefit of immunotherapy in hepatocellular carcinoma.
    J Gastroenterol. 2025 May 30. doi: 10.1007/s00535-025-02251.
    >> Share

  56. DING H, Lv H, Sui M, Wang X, et al
    Interaction of neuropilin-1 and hepatocyte growth factor/C-Met pathway in liver fibrosis progression in hepatocyte-specific NRP-1 knockout mice.
    J Gastroenterol. 2025 May 26. doi: 10.1007/s00535-025-02262.
    >> Share

  57. XIA M, Lu Y, Yin F, Cao Z, et al
    The external validation of Dallas Steatosis Index among Asian population: a useful tool for metabolic dysfunction-associated steatotic liver disease identification and prevention.
    J Gastroenterol. 2025;60:621-631.
    >> Share

    April 2025
  58. ZHANG Y, Che N, Wang S, Meng J, et al
    Correction: Nrf2/ASPM axis regulated vasculogenic mimicry formation in hepatocellular carcinoma under hypoxia.
    J Gastroenterol. 2025 Apr 23. doi: 10.1007/s00535-025-02246.
    >> Share

  59. OURA K, Morishita A, Yano R, Manabe T, et al
    Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma.
    J Gastroenterol. 2025 Apr 3. doi: 10.1007/s00535-025-02239.
    >> Share

  60. HANAMATSU H, Suda G, Ohara M, Ogawa K, et al
    Elevated A2F bisect N-glycans of serum IgA reflect progression of liver fibrosis in patients with MASLD.
    J Gastroenterol. 2025;60:456-468.
    >> Share

    March 2025
  61. MIWA T, Tsuruoka M, Ueda H, Abe T, et al
    Current management and future perspectives of covert hepatic encephalopathy in Japan: a nationwide survey.
    J Gastroenterol. 2025 Mar 7. doi: 10.1007/s00535-025-02232.
    >> Share

  62. AOKI T, Kudo M, Nishida N, Ueshima K, et al
    Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.
    J Gastroenterol. 2025 Mar 7. doi: 10.1007/s00535-025-02233.
    >> Share

  63. DU T, Huang Y, Lv Y, Yuan G, et al
    Liver fibrotic burden across the spectrum of hypothyroidism.
    J Gastroenterol. 2025;60:315-327.
    >> Share

  64. WANG H, Liu Z, Fan H, Guo C, et al
    Association between advanced fibrosis and epigenetic age acceleration among individuals with MASLD.
    J Gastroenterol. 2025;60:306-314.
    >> Share

    February 2025
  65. NISHIMURA T, Tada T, Akita T, Kondo R, et al
    Diagnostic performance of attenuation imaging versus controlled attenuation parameter for hepatic steatosis with MRI-based proton density fat fraction as the reference standard: a prospective multicenter study.
    J Gastroenterol. 2025 Feb 24. doi: 10.1007/s00535-025-02224.
    >> Share

  66. TANAKA A, Notohara K, Tobari M, Abe M, et al
    A clinicopathological study of IgG4-related autoimmune hepatitis and IgG4-hepatopathy.
    J Gastroenterol. 2025 Feb 8. doi: 10.1007/s00535-025-02221.
    >> Share

  67. KOGISO T, Ogasawara Y, Taniai M, Shimada E, et al
    Impact of ursodeoxycholic acid treatment on Fontan-associated liver disease.
    J Gastroenterol. 2025;60:210-221.
    >> Share

  68. KURODA H, Abe T, Kamiyama N, Oguri T, et al
    Novel subharmonic-aided pressure estimation for identifying high-risk esophagogastric varices.
    J Gastroenterol. 2025;60:187-196.
    >> Share

    January 2025
  69. WEN C, Tao H, Chen H, Pu W, et al
    Single-cell RNA sequencing and functional analysis reveal the role of altered glycosylation levels of hepatic macrophages in liver cirrhosis.
    J Gastroenterol. 2025 Jan 31. doi: 10.1007/s00535-025-02218.
    >> Share

  70. ZHANG X, Li J, Yao Y, Zhou M, et al
    Migrasome-related prognostic signature TSPAN4 correlates with immune infiltrates and metabolic disturbances in hepatocellular carcinoma.
    J Gastroenterol. 2025 Jan 12. doi: 10.1007/s00535-025-02212.
    >> Share

  71. KASAI Y, Ito T, Masui T, Nagai K, et al
    Liver transplantation for gastroenteropancreatic neuroendocrine liver metastasis: optimal patient selection and perioperative management in the era of multimodal treatments.
    J Gastroenterol. 2025;60:1-9.
    >> Share

    December 2024
  72. ZHANG F, Wang YS, Li SP, Zhao B, et al
    Alpha-fetoprotein combined with initial tumor shape irregularity in predicting the survival of patients with advanced hepatocellular carcinoma treated with immune-checkpoint inhibitors: a retrospective multi-center cohort study.
    J Gastroenterol. 2024 Dec 23. doi: 10.1007/s00535-024-02202.
    >> Share

  73. MIURA R, Ono A, Nakahara H, Shirane Y, et al
    Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02185.
    >> Share

  74. KAMADA Y, Sumida Y, Takahashi H, Fujii H, et al
    Utility of Mac-2 binding protein glycosylation isomer as an excellent biomarker for the prediction of liver fibrosis, activity, and hepatocellular carcinoma onset: an expert review.
    J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02179.
    >> Share

  75. IMAI Y, Koizumi Y, Hiasa Y, Hirooka M, et al
    Standard technique in Japan for measuring hepatic venous pressure gradient.
    J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02182.
    >> Share

  76. RABIU L, Zhang P, Afolabi LO, Saliu MA, et al
    Immunological dynamics in MASH: from landscape analysis to therapeutic intervention.
    J Gastroenterol. 2024;59:1053-1078.
    >> Share

    November 2024
  77. CAO Z, Yang Y, Liu S, Sun L, et al
    FGFR2 fusions assessed by NGS, FISH, and immunohistochemistry in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2024 Nov 13. doi: 10.1007/s00535-024-02175.
    >> Share

    October 2024
  78. LIU WJ, Wu WJ, Lin CL, Liu CJ, et al
    Impact of age at HBsAg seroclearance on hepatic outcomes and life expectancy in men with chronic HBV infection based on multi-state modeling of the natural history.
    J Gastroenterol. 2024 Oct 22. doi: 10.1007/s00535-024-02162.
    >> Share

  79. UENO M, Takeda H, Takai A, Morimura H, et al
    Publisher Correction: CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study.
    J Gastroenterol. 2024 Oct 21. doi: 10.1007/s00535-024-02159.
    >> Share

  80. SOMA N, Uchida Y, Kouyama JI, Naiki K, et al
    Serum zinc levels as predictors of covert hepatic encephalopathy in patients with liver cirrhosis.
    J Gastroenterol. 2024 Oct 16. doi: 10.1007/s00535-024-02160.
    >> Share

  81. KAWAGUCHI T, Fujishima Y, Wakasugi D, Io F, et al
    Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan.
    J Gastroenterol. 2024 Oct 11. doi: 10.1007/s00535-024-02158.
    >> Share

  82. HANAI T, Nishimura K, Unome S, Miwa T, et al
    Response to letter to the editor regarding: "Alcohol-associated liver disease increases the risk of muscle reduction and mortality in patients with cirrhosis".
    J Gastroenterol. 2024 Oct 4. doi: 10.1007/s00535-024-02153.
    >> Share

  83. SANCHEZ-MONTEAGUDO A, Ripolles E, Murillo O, Domenech S, et al
    Profile of plasma microRNAs as a potential biomarker of Wilson's disease.
    J Gastroenterol. 2024;59:921-931.
    >> Share

    September 2024
  84. KUNZLER IL, Da Croce MA, Fornari F
    Alcohol-associated liver disease increases the risk of muscle loss and mortality in patients with cirrhosis.
    J Gastroenterol. 2024 Sep 23. doi: 10.1007/s00535-024-02154.
    >> Share

  85. UENO M, Takeda H, Takai A, Morimura H, et al
    CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study.
    J Gastroenterol. 2024 Sep 18. doi: 10.1007/s00535-024-02150.
    >> Share

  86. YAMAUCHI K, Maekawa S, Osawa L, Komiyama Y, et al
    Single-molecule sequencing of the whole HCV genome revealed envelope deletions in decompensated cirrhosis associated with NS2 and NS5A mutations.
    J Gastroenterol. 2024 Sep 3. doi: 10.1007/s00535-024-02146.
    >> Share

  87. KAWAGUCHI T, Murotani K, Kajiyama H, Obara H, et al
    Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials.
    J Gastroenterol. 2024;59:836-848.
    >> Share

    August 2024
  88. YU C, Tang Y, Liu M, Xu X, et al
    The risk stratification and predictive performance of a new combined polygenic risk score for hepatocellular carcinoma.
    J Gastroenterol. 2024 Aug 10. doi: 10.1007/s00535-024-02144.
    >> Share

  89. ZHANG Y, Che N, Wang S, Meng J, et al
    Nrf2/ASPM axis regulated vasculogenic mimicry formation in hepatocellular carcinoma under hypoxia.
    J Gastroenterol. 2024 Aug 3. doi: 10.1007/s00535-024-02140.
    >> Share

    July 2024
  90. HANAI T, Nishimura K, Unome S, Miwa T, et al
    Alcohol-associated liver disease increases the risk of muscle loss and mortality in patients with cirrhosis.
    J Gastroenterol. 2024 Jul 28. doi: 10.1007/s00535-024-02137.
    >> Share

  91. HAO Y, Hao Z, Zeng X, Lin Y, et al
    Gut microbiota and metabolites of cirrhotic portal hypertension: a novel target on the therapeutic regulation.
    J Gastroenterol. 2024 Jul 19. doi: 10.1007/s00535-024-02134.
    >> Share

  92. AMPUERO J, Aller R, Gallego-Duran R, Crespo J, et al
    The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis.
    J Gastroenterol. 2024;59:586-597.
    >> Share

    June 2024
  93. MIWA T, Utakata Y, Hanai T, Aiba M, et al
    Acute kidney injury development is associated with mortality in Japanese patients with cirrhosis: impact of amino acid imbalance.
    J Gastroenterol. 2024 Jun 11. doi: 10.1007/s00535-024-02126.
    >> Share

  94. WAKABAYASHI SI, Tamaki N, Kimura T, Umemura T, et al
    Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease.
    J Gastroenterol. 2024;59:494-503.
    >> Share

  95. HIROOKA M, Ogawa S, Koizumi Y, Yoshida Y, et al
    iATT liver fat quantification for steatosis grading by referring to MRI proton density fat fraction: a multicenter study.
    J Gastroenterol. 2024;59:504-514.
    >> Share

  96. MINO M, Sano A, Kakazu E, Matsubara H, et al
    Differences in branched-chain amino acid to tyrosine ratio (BTR) among etiologies of chronic liver disease progression compared to healthy adults.
    J Gastroenterol. 2024;59:483-493.
    >> Share

    May 2024
  97. ATSUKAWA M, Tsubota A, Kondo C, Toyoda H, et al
    ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis.
    J Gastroenterol. 2024 May 10. doi: 10.1007/s00535-024-02109.
    >> Share

    April 2024
  98. FUJIWARA K, Kondo T, Fujimoto K, Yumita S, et al
    Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma.
    J Gastroenterol. 2024 Apr 7. doi: 10.1007/s00535-024-02097.
    >> Share

  99. CORNEJO-PAREJA I, Amiar MR, Ocana-Wilhelmi L, Soler-Humanes R, et al
    Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism.
    J Gastroenterol. 2024;59:329-341.
    >> Share

    March 2024
  100. XIN HY, Zou JX, Sun RQ, Hu ZQ, et al
    Characterization of tumor microbiome and associations with prognosis in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2024 Mar 10. doi: 10.1007/s00535-024-02090.
    >> Share

  101. WANG J, Zhang H, Chen L, Fu K, et al
    CircDCBLD2 alleviates liver fibrosis by regulating ferroptosis via facilitating STUB1-mediated PARK7 ubiquitination degradation.
    J Gastroenterol. 2024;59:229-249.
    >> Share

    February 2024
  102. WU C, Li J, Jia H, Zhao J, et al
    Indoleamine 2,3-dioxygenase 1-mediated iron metabolism in macrophages contributes to lipid deposition in nonalcoholic steatohepatitis.
    J Gastroenterol. 2024 Feb 24. doi: 10.1007/s00535-024-02082.
    >> Share

  103. NAMISAKI T, Sato S, Yoshiji H
    Role of combined aerobic and resistance exercise in liver cirrhosis.
    J Gastroenterol. 2024 Feb 8. doi: 10.1007/s00535-024-02078.
    >> Share

    January 2024
  104. KOBAYASHI T, Iwaki M, Nogami A, Kawamura N, et al
    Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography.
    J Gastroenterol. 2024;59:56-65.
    >> Share

  105. HANAI T, Nishimura K, Unome S, Miwa T, et al
    A survey questionnaire evaluating physical activity patterns and determinants in patients with chronic liver disease.
    J Gastroenterol. 2024;59:45-55.
    >> Share

    December 2023
  106. KAWAGUCHI T, Kawaguchi A, Hashida R, Nakano D, et al
    Resistance exercise in combination with aerobic exercise reduces the incidence of serious events in patients with liver cirrhosis: a meta-analysis of randomized controlled trials.
    J Gastroenterol. 2023 Dec 30. doi: 10.1007/s00535-023-02060.
    >> Share

  107. ICHITA C, Goto T, Shimizu S
    Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data.
    J Gastroenterol. 2023 Dec 19. doi: 10.1007/s00535-023-02066.
    >> Share

  108. UENO M, Fujiwara T, Tokumasu H, Mizuno M, et al
    Reply to "Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data".
    J Gastroenterol. 2023 Dec 13. doi: 10.1007/s00535-023-02067.
    >> Share

    November 2023
  109. YANG Z, Shi M, Liang Y, Zhang F, et al
    Three-dimensional chromatin landscapes in hepatocellular carcinoma associated with hepatitis B virus.
    J Gastroenterol. 2023 Nov 5. doi: 10.1007/s00535-023-02053.
    >> Share

  110. TADA F, Hiraoka A, Tada T, Hirooka M, et al
    Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varices.
    J Gastroenterol. 2023;58:1134-1143.
    >> Share

    October 2023
  111. WANG H, Li Y, Pu X, Liang X, et al
    MGAT5/TMEM163 variant is associated with prognosis in ursodeoxycholic acid-treated patients with primary biliary cholangitis.
    J Gastroenterol. 2023 Oct 16. doi: 10.1007/s00535-023-02045.
    >> Share

  112. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
    Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.
    J Gastroenterol. 2023 Oct 13. doi: 10.1007/s00535-023-02039.
    >> Share

  113. CRANE H, Gofton C, Sharma A, George J, et al
    MAFLD: an optimal framework for understanding liver cancer phenotypes.
    J Gastroenterol. 2023;58:947-964.
    >> Share

    September 2023
  114. KADO A, Tsutsumi T, Yotsuyanagi H, Ikeuchi K, et al
    Noninvasive approach to indicate risk factors of nonalcoholic steatohepatitis overlapping autoimmune hepatitis based on peripheral lymphocyte pattern.
    J Gastroenterol. 2023 Sep 14. doi: 10.1007/s00535-023-02038.
    >> Share

  115. WEI M, Chen Y, Wang M, Li J, et al
    Correction: Partial splenic embolization combined with endoscopic therapies and vasoconstrictive drugs reduces rebleeding in cirrhosis patients with acute variceal bleeding and hypersplenism: a multicenter randomized controlled trial.
    J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02036.
    >> Share

  116. OZONO Y, Kawakami H, Uchiyama N, Hatada H, et al
    Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary-pancreatic cancers.
    J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02037.
    >> Share

  117. LIU C, Zhu S, Zhang J, Wu P, et al
    Global, regional, and national burden of liver cancer due to non-alcoholic steatohepatitis, 1990-2019: a decomposition and age-period-cohort analysis.
    J Gastroenterol. 2023 Sep 4. doi: 10.1007/s00535-023-02040.
    >> Share

    July 2023
  118. WEI M, Chen Y, Wang M, Li J, et al
    Partial splenic embolization combined with endoscopic therapies and vasoconstrictive drugs reduces rebleeding in cirrhosis patients with acute variceal bleeding and hypersplenism: a multicenter randomized controlled trial.
    J Gastroenterol. 2023 Jul 24. doi: 10.1007/s00535-023-02027.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016